HK inno.N
About
Since its establishment in 1984, inno.N has grown into one of Korea’s leading pharmaceutical companies, with strong technology-driven competitiveness in the fields of prescription drugs, active pharmaceutical ingredients (APIs), and health & beauty care.
Leveraging the development and blockbuster success of K-CAB, Korea’s 30th novel drug, inno.N is now focusing its capabilities on developing high-value innovative new drugs and biopharmaceuticals.
With many years of accumulated experience in global sales and marketing, inno.N is introducing its prescription drugs, APIs, and health & beauty products to markets around the world. Backed by proven success and R&D tailored to global needs, the company is expanding exports to Japan, Southeast Asia, and Latin America, while also strengthening its global marketing capabilities in Europe and the Middle East.
Based on its professional sales, marketing, and R&D expertise in new drugs and biologics, inno.N actively pursues partnerships with global pharmaceutical companies and promising R&D ventures. Through alliances with multinational pharmaceutical companies such as AstraZeneca, Takeda, Eisai, and Daiichi Sankyo, inno.N not only delivers innovative medicines to the Korean market, but also introduces its own novel and biopharmaceutical products globally — showcasing the competitiveness of Korea’s leading biohealth company to the world.
-------------------------------------------------------------------------------------------------------------------
My name is Daeik Kim, and I serve as the Head of the Liaison Office and Business Development Manager at HK inno.N Germany.
Our headquarters is a pharmaceutical company based in South Korea, operating as a subsidiary of Kolmar Korea. We specialize in both new drug development and the sale of generic drugs.
Our annual revenue is approximately 600 million EUR, and we have a workforce of around 1,600 employees.
HK inno.N has a strong interest in treatments for various therapeutic areas, including dermatological diseases, metabolic diseases (such as obesity, hypertension, hyperlipidemia), gastrointestinal disorders, and oncology. We also possess a diverse pipeline of drug candidates in these areas.
We warmly welcome inquiries for various partnership opportunities.
LIFE SCIENCES
NETWORKING INTERESTS
Additional questions
NETWORKING/COLLABORATION INTERESTS?
Representatives
Head of Liaison Office(Business Development)
HK inno.N